NDAINJECTIONINJECTABLE
Approved
Dec 1952
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PERMAPEN (penicillin g benzathine) by R-Pharm US is mechanism of action penicillin g exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. Approved for the treatment of infections due to penicillin-g-sensitive microorganisms, very prolonged serum levels common to this particular dosage form. First approved in 1952.
Drug data last refreshed Yesterday
Mechanism of Action
Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.
Worked on PERMAPEN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.